Study Shows Addyi is Not "Female Viagra" by Any Stretch of the Imagination

According to an article published online by JAMA Internal Medicine (JAMA Intern Med. Published online February 29, 2016. doi:10.1001/jamainternmed.2015.8565) found that flibanserin (Addyi), which was approved last year by the FDA to treat hypoactive (low) sexual desire disorder (HSDD) in premenopausal women, had marginal clinical benefits and significant increases in some adverse events.

Loes Jaspers, M.D., of the Erasmus University Medical Center, Rotterdam, the Netherlands, and coauthors reviewed eight clinical trials (five published and three unpublished) that included 5,914 women to examine the efficacy and safety Addyi.

Here's what they found.

Read more »